445 results on '"Padalko, Elizaveta"'
Search Results
2. Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients
3. Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial
4. Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance
5. Evaluation of the applicability of internal controls on self-collected samples for high-risk human papillomavirus is needed
6. Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
7. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
8. Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).
9. Importance of anti-SARS-CoV-2 assay antigenic composition as revealed by the results of the Belgian external quality assessment (EQA) scheme
10. Screening algorithms for HBV, HCV, HIV and syphilis in an anatomical donation program
11. Comparison of 4 commercial enzyme immunoassays for serology testing of human parvovirus B19 infection
12. SARS-CoV-2 Seropositivity in Nursing Home Staff and Residents during the First SARS-CoV-2 Wave in Flanders, Belgium.
13. Follow-Up of SARS-CoV-2 Antibody Levels in Belgian Nursing Home Residents and Staff Two, Four and Six Months after Primary Course BNT162b2 Vaccination.
14. Prospective multicenter comparison of urine culture with PCR on dried blood spots using 2 different extraction and PCR methods in neonates suspected for congenital cytomegalovirus infection
15. Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022
16. Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same?
17. Combined oropharyngeal/nasal swab is equivalent to nasopharyngeal sampling for SARS-CoV-2 diagnostic PCR
18. Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients
19. Evaluation of a smartphone‐operated point‐of‐care device using loop‐mediated isothermal amplification technology for rapid and remote detection of SARS‐CoV‐2
20. Interpretation of EBV serology for human body material donors: Is there a need for early antigen IgG and heterophile antibodies testing?
21. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium
22. Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium
23. Human bocavirus infection in Belgian children with respiratory tract disease
24. Peroxynitrite Inhibition of Coxsackievirus Infection by Prevention of Viral RNA Entry
25. Public Health Impact of Congenital Toxoplasmosis and Cytomegalovirus Infection in Belgium, 2013: A Systematic Review and Data Synthesis
26. Intra‐ and interlaboratory reproducibility of the RIATOL qPCR HPV genotyping assay
27. Does screening for Neisseria gonorrhoeae and Chlamydia trachomatis affect the incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP) ? Results from a randomized, multicentre controlled trial (the Gonoscreen study)
28. No Significant Association between 25-OH Vitamin D Status and SARS-CoV-2 Antibody Response after COVID-19 Vaccination in Nursing Home Residents and Staff
29. Effect of screening for Neisseria gonorrhoeaeand Chlamydia trachomatison incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial
30. Universal cervical cancer control through a right to health lens: refocusing national policy and programmes on underserved women
31. Risk Factors for Natural Hearing Evolution in Newborns With Congenital Cytomegalovirus Infection.
32. Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations
33. Estimation of the real magnitude of antimicrobial resistance of Mycoplasma genitalium in Belgium by implementing a prospective surveillance programme.
34. Comparison between the Roche Cobas 4800 Human Papillomavirus (HPV), Abbott RealTime High-Risk HPV, Seegene Anyplex II HPV28, and Novel Seegene Allplex HPV28 Assays for High-Risk HPV Detection and Genotyping in Mocked Self-Samples
35. The prognosis of hepatitis delta infections in Belgium is poor and determined by the hepatitis delta viremia
36. Preanalytical variables influencing the interpretation and reporting of biological tests on blood samples of living and deceased donors for human body materials
37. Sero-epidemiological status and risk factors of toxoplasmosis in pregnant women in Northern Vietnam
38. Quality assurance in human papillomavirus testing for primary cervical screening
39. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study
40. Human Papillomavirus Negative High Grade Cervical Lesions and Cancers: Suggested Guidance for Hpv Testing Quality Assurance
41. Comparison between the Roche Cobas 4800 Human Papillomavirus (HPV), Abbott RealTime High-Risk HPV, Seegene Anyplex II HPV28, and Novel Seegene Allplex II HPV28 assays for high-risk HPV detection and genotyping in mocked self-samples
42. Hepatitis E virus serology and PCR: does the methodology matter?
43. Comparative analysis of cervical cytology and human papillomavirus genotyping by three different methods in a routine diagnostic setting
44. Risk Factors for Hearing Loss at Birth in Newborns With Congenital Cytomegalovirus Infection
45. Diagnostic performance of the SARS-CoV-2 S1RBD IgG ELISA (ImmunoDiagnostics) for the quantitative detection of SARS-CoV-2 antibodies on dried blood spots
46. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening
47. Screening of chlamydia trachomatis in non-partner donors: situation of stored donations and proposal for periodic screening
48. Delayed presentations of severe combined immunodeficiency during the SARS‑CoV‑2 pandemic
49. Correction to: Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations
50. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.